Sonoma Pharmaceuticals, Inc. (SNOA)
| Market Cap | 14.05M |
| Revenue (ttm) | 21.05M |
| Net Income (ttm) | -1.66M |
| Shares Out | 2.05M |
| EPS (ttm) | -0.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $7.16 |
| Previous Close | $6.81 |
| Change ($) | 0.35 |
| Change (%) | 5.14% |
| Day's Open | 6.78 |
| Day's Range | 6.65 - 7.30 |
| Day's Volume | 47,927 |
| 52-Week Range | 3.55 - 19.60 |
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range ...
New York, New York--(Newsfile Corp. - February 19, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholder...
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range ...
NEW YORK, Feb. 15, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pha...
Los Angeles, California--(Newsfile Corp. - February 8, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inves...
LOS ANGELES, Feb. 1, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sonoma Pharmac...
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range ...
NEW YORK, Jan. 18, 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceutic...
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range ...
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NA...
NEW YORK, Dec. 19, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. (“Sonoma” or the “Company”) (NASDAQ: SNOA). Such inve...
Sonoma Pharmaceuticals (NASDAQ: SNOA) shares are trading higher on Friday after the company announced a partnership with Gabriel Science for dental markets. Sonoma is engaged in identifying, d...
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals and Gabriel Science enter into distribution agreement for the sale of HOCl-products into the dental markets.
New York, New York--(Newsfile Corp. - December 16, 2020) - Pomerantz LLP is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. ("Sonoma" or the "Company") (NASDAQ: SNO...
NEW YORK, Dec. 12, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. (“Sonoma” or the “Company”) (NASDAQ: SNOA). Such inve...
Sonoma Pharmaceuticals (SNOA) is in the news Friday after announcing a deal with Crown Laboratories that has SNOA stock on the rise. The post Sonoma Pharmaceuticals News Alert: Why SNOA Stock ...
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals and Crown Laboratories announce an exclusive partnership to launch Microcyn® Technology-based anti-itch OTC products.
New York, New York--(Newsfile Corp. - December 8, 2020) - Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholder...
NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. (“Sonoma” or the “Company”) (NASDAQ: SNOA). Such inve...
NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. (“Sonoma” or the “Company”) (NASDAQ: SNOA). Such invest...
LOS ANGELES--(BUSINESS WIRE)---- $SNOA #SNOA--ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sonoma Pharmaceuticals, Inc.
NEW YORK, Nov. 25, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. ("Sonoma" or the "Company") (NASDAQ: SNOA). Such investors ...
Investors can contact the law firm at no cost to learn more about recovering their losses Investors can contact the law firm at no cost to learn more about recovering their losses
Los Angeles, California--(Newsfile Corp. - November 25, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inve...
NEW YORK, Nov. 24, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceutic...
LOS ANGELES--(BUSINESS WIRE)---- $SNOA #SNOA--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sonoma Pharmaceuticals, Inc.
New York, New York--(Newsfile Corp. - November 24, 2020) - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of ...
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc...
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range ...
The Covid-19 pandemic has given a significant boost to many industries such as manufacturers of gloves, masks, sanitizers, PPE (personal protective equipment), health insurance providers, and ...
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc.
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc.
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals (SNOA) is in the news Wednesday after an update concerning its Microsafe disinfectant sent SNOA stock soaring. The post Sonoma Pharmaceuticals News: Why SNOA Stock Is Sk...
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc.
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range ...
Sonoma Pharmaceuticals (NASDAQ: SNOA) shares are trading higher on Friday. The company announced that its Nanocyn Disinfectant & Sanitizer has received approval to be entered into the Australi...
Sonoma Pharmaceuticals (SNOA) is in the news Friday after approval for a disinfectant of the novel coronavirus sent SNOA stock skyrocketing. The post Sonoma Pharmaceuticals News: SNOA Stock Sk...
Shares of Sonoma Pharmaceuticals Inc. SNOA, +216.63% nearly tripled on heavy volume in premarket trading Friday
PETALUMA, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company dedicated to identifying, developing and commercializing u...
PETALUMA, Calif., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company dedicated to identifying, developing and commercializing u...
PETALUMA, Calif., Nov. 29, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced the closing of a public offering of 446,577 shares of common stock at a public...
PETALUMA, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced the pricing of its previously announced “best efforts” public offering of shar...
PETALUMA, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced the launch of a “best efforts” public offering of shares of its common stock.
Agreement with CEO and Interim CFO Bubba Sandford ends Amy Trombly Appointed as Interim CEO John Dal Poggetto Appointed as New CFO
About SNOA
Sonoma Pharmaceuticals, develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of n... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Jan 25, 2007 |
| CEO Amy Trombly | Employees 19 |
| Stock Exchange NASDAQ | Ticker Symbol SNOA |
Financial Performance
In 2019, SNOA's revenue was $18.94 million, a decrease of -0.18% compared to the previous year's $18.97 million. Losses were -$2.95 million, -75.03% less than in 2018.
Analyst Forecasts
The average 12-month stock price forecast for SNOA is 9.00, which is an increase of 25.70% from the latest price.